Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cytarabine + filgrastim + vincristine + idarubicin + prednisone + rituximab
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous, Oral
01
Overview
FLAG-VIPR is an intensive hybrid chemotherapy regimen used primarily for the treatment of Mixed Phenotype Acute Leukemia (MPAL). It combines the FLAG backbone (Fludarabine, Cytarabine, and G-CSF) typically used in acute myeloid leukemia (AML) with components of acute lymphoblastic leukemia (ALL) directed therapy, including Vincristine, Idarubicin, Prednisone, and the anti-CD20 monoclonal antibody Rituximab. This regimen aims to address the dual-lineage nature of MPAL blasts by incorporating agents effective against both myeloid and lymphoid malignancies. The G-CSF (filgrastim) component is used both to prime leukemia blasts for increased sensitivity to cytarabine and to accelerate neutrophil recovery following intensive chemotherapy.
- Other names
- FLAG-VIPR regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)DNADNA polymerase familyTOP2A (DNA topoisomerase II)CSF3R (Granulocyte colony-stimulating factor receptor)GR (Glucocorticoid receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on fludarabine + cytarabine + filgrastim + vincristine + idarubicin + prednisone + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cytarabine + filgrastim + vincristine + idarubicin + prednisone + rituximab.